SCHEDULE: Hexstone Capital Reduces Cellectar Stake Below 5%

Hexstone Capital LLC and Brendan O'Neil have filed an amendment indicating they are no longer beneficial owners of more than 5% of Cellectar Biosciences, Inc. common stock.

Summary

• Hexstone Capital LLC and Brendan O'Neil have filed an Amendment No. 1 to their Schedule 13G, indicating they have ceased to be beneficial owners of more than five percent of Cellectar Biosciences, Inc.'s common stock.
• This filing serves as an "exit filing" for both reporting persons, signifying their ownership has fallen below the 5% disclosure threshold.
• As of December 31, 2025, the reporting persons beneficially owned an aggregate of 216,130 shares of Cellectar Biosciences, Inc. common stock.
• This represents 4.9% of the total outstanding common stock, based on 4,240,134 shares outstanding as of November 21, 2025, as disclosed in the issuer's prospectus.
• The beneficial ownership consists of 125,000 shares of common stock directly held and 91,130 shares issuable upon exercise of Series A common stock purchase warrants.
• Further exercises of these warrants are subject to a 4.99% beneficial ownership limitation provision (the "Blocker"), which prevents ownership from exceeding this threshold.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral to slightly negative development. While a routine regulatory filing, the reduction of a significant investor's stake below 5% could imply a shift in investment strategy or conviction, which the market may interpret cautiously.

Negatives

• Hexstone Capital LLC and Brendan O'Neil have reduced their beneficial ownership in Cellectar Biosciences, Inc. to below 5%, signaling a decreased stake by a previously significant investor.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that a reduction in a significant investor's stake, particularly below the 5% threshold requiring public disclosure, can sometimes be interpreted by the market as a shift in investor sentiment or a strategic portfolio adjustment. For a biotechnology company like Cellectar Biosciences, such a move by an institutional investor warrants attention, though the specific reasons for the reduction are not disclosed in this regulatory filing.

Stakeholder Impact

• Shareholders: May interpret the reduction in Hexstone Capital's stake as a potential signal regarding the company's future prospects or the investor's portfolio strategy.

Key Dates

Recommendation

The filing indicates a significant investor, Hexstone Capital LLC, has reduced its stake in Cellectar Biosciences, Inc. to below 5%. While this is a factual regulatory disclosure and the reasons for the reduction are not provided, a decrease in a major investor's position can sometimes be a cautious signal. Without further information on the investor's rationale or any new company-specific developments, a 'hold' recommendation is prudent. Investors should monitor for additional news or company performance updates to assess the implications of this ownership change.

Keywords

Cellectar Biosciences, Hexstone Capital, Brendan O'Neil, Schedule 13G/A, Beneficial Ownership, Common Stock, Warrants, Exit Filing, Investment, Biotechnology